We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+15.54%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$174M
AUM Growth
+$18.3M
Cap. Flow
-$2.25M
Cap. Flow %
-1.29%
Top 10 Hldgs %
90.88%
Holding
46
New
4
Increased
6
Reduced
8
Closed
6

Top Buys

Rank Stock Value
1
AXDX
Accelerate Diagnostics
AXDX
+$1.61M
2
KURA icon
Kura Oncology
KURA
+$829K
3
NBIX icon
Neurocrine Biosciences
NBIX
+$686K
4
WMGI
Wright Medical Group Inc
WMGI
+$650K
5
CORT icon
Corcept Therapeutics
CORT
+$361K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$2.31M
2
SWN
Southwestern Energy Company
SWN
+$1.22M
3
CLR
CONTINENTAL RESOURCES INC.
CLR
+$947K
4
GILD icon
Gilead Sciences
GILD
+$936K
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$626K

Sector Composition

Rank Sector Weight
1 Healthcare 93.93%
2 Energy 2.09%
3 Consumer Staples 1.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$93M 53.53%
776,351
-20,000
-3% -$2.31M
AXDX
2
DELISTED
Accelerate Diagnostics
AXDX
$46.3M 26.68%
215,580
+8,824
+4% +$1.61M
VRML
3
DELISTED
Vermillion, Inc.
VRML
$4.89M 2.82%
2,717,514
– –
YTEN
4
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$3.14M 1.81%
236
– –
CFRX
5
DELISTED
ContraFect Corporation
CFRX
$2.26M 1.3%
594
+25
+4% +$83.5K
EQT icon
6
EQT Corp
EQT
$31B
$2.21M 1.27%
77,705
– –
COLL icon
7
Collegium Pharmaceutical
COLL
$1.17B
$1.62M 0.93%
58,768
– –
MDVN
8
DELISTED
MEDIVATION, INC.
MDVN
$1.58M 0.91%
32,760
– –
MASI
9
DELISTED
Masimo
MASI
$1.52M 0.87%
36,600
– –
OMED
10
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$1.32M 0.76%
58,689
– –
NBIX icon
11
Neurocrine Biosciences
NBIX
$17.2B
$1.31M 0.76%
23,200
+13,500
+139% +$686K
HNSN
12
DELISTED
HANSEN MEDICAL, INC. COM NEW
HNSN
$1.23M 0.71%
528,143
-1
-0% -$3
BIOL
13
DELISTED
Biolase, Inc.
BIOL
$1.08M 0.62%
103
+8
+8% +$87.4K
QTNT
14
DELISTED
Quotient Limited Ordinary Shares
QTNT
$931K 0.54%
1,455
– –
KURA icon
15
Kura Oncology
KURA
$964M
$884K 0.51%
+105,285
New +$829K
QDEL icon
16
QuidelOrtho
QDEL
$1.19B
$826K 0.48%
38,975
– –
MRK icon
17
Merck
MRK
$315B
$792K 0.46%
15,720
– –
WMGI
18
DELISTED
Wright Medical Group Inc
WMGI
$725K 0.42%
+30,000
New +$650K
OVV icon
19
Ovintiv
OVV
$16.2B
$673K 0.39%
26,460
– –
ARAY icon
20
Accuray
ARAY
$30.8M
$643K 0.37%
95,300
-25,000
-21% -$161K
NXTM
21
DELISTED
NxStage Medical Inc.
NXTM
$563K 0.32%
25,700
+11,000
+75% +$205K
CERS icon
22
Cerus
CERS
$627M
$525K 0.3%
83,000
– –
PTCT icon
23
PTC Therapeutics
PTCT
$6.52B
$483K 0.28%
14,900
-2,000
-12% -$58.9K
OXFD
24
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$463K 0.27%
40,303
+25,000
+163% +$309K
CORT icon
25
Corcept Therapeutics
CORT
$9.72B
$398K 0.23%
+80,000
New +$361K
1
2

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2015 Portfolio in Review

As of Q4 2015, Birchview Capital held 46 positions worth $174M, up 12% from $155M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Birchview Capital's Q4 2015 filing shows 4 new, 6 increased, 8 reduced and 6 closed positions. Its largest new stake was Kura Oncology: 105,285 shares worth $884K. The largest sale was Celgene Corp, an estimated $2.31M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 90% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q4 2015 buy was Kura Oncology: 105,285 shares worth $884K.
  • Birchview Capital added most to Accelerate Diagnostics in Q4 2015, an estimated $1.61M increase.
  • Birchview Capital's biggest Q4 2015 reduction was Celgene Corp, cutting an estimated $2.31M.
  • Birchview Capital fully exited Southwestern Energy Company in Q4 2015, selling an estimated $1.22M.
  • Birchview Capital's ten largest holdings make up 91% of its $174M portfolio in Q4 2015.
  • Birchview Capital opened 4 new positions and closed 6 in Q4 2015.
  • Birchview Capital's portfolio value rose 12% quarter-over-quarter to $174M.

Based on Birchview Capital's 13F filing for Q4 2015, filed 8 Feb 2016.